title: Stratified medicines: towards better treatment for disease.
authors.affiliation: University of Oxford, Oxford, UK. Electronic address: info@medsci.ac.uk.
authors.forename: John
authors.initials: J
authors.lastname: Bell
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000378:metabolism; D003142:Communication; D000077547:Crizotinib; D004496:Education, Continuing / Q000639:trends*; D005260:Female; D006282:Health Personnel / Q000193:education*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000378:metabolism; D058990:Molecular Targeted Therapy / Q000639:trends*; D009313:National Health Programs; D015514:Oncogene Proteins, Fusion / Q000187:drug effects / Q000378:metabolism; D057285:Precision Medicine / Q000639:trends*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D011720:Pyrazoles / Q000494:pharmacology; D011725:Pyridines / Q000494:pharmacology; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism; D000068878:Trastuzumab; D006113:United Kingdom
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000077547:Crizotinib; D015514:Oncogene Proteins, Fusion; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011725:Pyridines; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C522504:EML4-ALK fusion protein, human; C508053:ERBB2 protein, human